Derek Maetzold

President and Chief Executive Officer
Castle Biosciences

Biography

Derek Maetzold founded Castle Biosciences in 2007 and currently serves as President, Chief Executive Officer and a member of the Company’s board of directors. Castle is a leading diagnostics company focused on improving health through innovative tests that guide patient care. With a strong foundation in dermatology, Castle develops personalized diagnostic tools designed to help clinicians make more informed decisions and improve patient outcomes across a range of diseases.

Mr. Maetzold founded Castle with the belief that incorporating personalized genomic information into clinical decision-making could meaningfully improve patient care. Under his leadership, Castle has established a growing portfolio of innovative diagnostic tests addressing unmet clinical needs in skin cancers, atopic dermatitis, Barrett’s esophagus and uveal melanoma. Building on its expertise in dermatologic diagnostics, Castle has expanded into inflammatory skin diseases with the development of AdvanceAD-Tx™, a gene expression profile test designed to inform systemic treatment decisions for patients with moderate-to-severe atopic dermatitis. The Company continues to advance innovation in dermatology through internal research and development and strategic collaborations, including the development of noninvasive electrical impedance spectroscopy (EIS)-based technology aimed at predicting disease flares in patients with atopic dermatitis.

Mr. Maetzold successfully led Castle through several rounds of private financing, its initial public offering in July 2019 and three acquisitions that expanded the Company’s commercial portfolio. Prior to founding Castle, he spent 25 years in pharmaceutical development and commercialization, with experience spanning multinational pharmaceutical companies and emerging biotechnology firms. His background includes new product development, business licensing and commercial oversight of therapies prior to regulatory approval.

Mr. Maetzold’s professional recognition includes CEO of the Year 2025 (U.S.) by The CEO Magazine, a 2025 Most Admired CEO Award from the Houston Business Journal, a 2025 Lifetime Achievement Award from the American Business Awards and a 2024 Ernst & Young Entrepreneur of the Year® Award for the Gulf South region.

He currently serves on the boards of PreludeDx™, the Coalition for 21st Century Medicine and IMPACT Melanoma. He is also a co-author of numerous scientific publications and a co-inventor of multiple technologies.